Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
These results show that retatrutide is effective in the management of type 2 diabetes and reduces the risk of cardiovascular disease
Current evidence does not support routine clinical use of GLP-1 medications specifically for alcohol cravings, and patients with alcohol use disorder should be referred to evidence-based treatments including behavioral interventions, mutual support groups, and FDA-approved pharmacotherapies such as naltrexone, acamprosate, and disulfiram
Just how valuable GLP-1 based drugs are can be seen from the fact that in 2022 they raised US$ 18.75 billion worldwide (Lloyd)
Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al
Medi-Cal dropping coverage Perhaps the most significant change for low-income populations was Medi-Cal, California Medicaid program, dropping GLP-1 weight loss coverage effective January 1, 2026
Without targeted policy interventions, such as expanded insurance coverage or income-based subsidy programs, the benefits of GLP-1 medications may continue to accrue disproportionately to higher-income populations, leaving behind the very communities most affected by obesity
US$ 20.52
US$ 21.41
US$ 22.60
US$ 23.69
US$ 20.54
US$ 25.16
